Microbot Medical® to Highlight Commercial Achievements Leading to the Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System at the 25th Annual Needham Virtual[...]

Microbot Medical^® to Highlight Commercial Achievements Leading to the Full Market Release (FMR) of the LIBERTY^® Endovascular Robotic System at the 25th Annual Needham Virtual Healthcare Conference

The presentation will be webcast live on April 15 at 10:15 a.m. ET. Continued Engagement with Healthcare Institutions Reflects Rising Momentum

HINGHAM, Mass., April 14, 2026 - Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it will highlight recent commercial achievements leading to the recent Full Market Release (FMR) of the LIBERTY System at the 25th Annual Needham Virtual Healthcare Conference, being held April 13-16^th. Harel Gadot, CEO, President & Chairman of Microbot Medical, will be presenting live at 10:15 a.m. ET on Wednesday, April 15, 2026. Mr. Gadot, along with other of Microbot's senior executives, will provide an overview of the Company and its strategic positioning, growth opportunities, and ability to address markets with multiple unmet needs, including physician radiation risks, physical strain and staffing issues.

The presentation will be webcast live and may be accessed via the 'Investors' section on Microbot Medical's website at https://ir.microbotmedical.com/. Additionally, the Microbot Medical team will meet with healthcare-focused institutional investors through a series of pre-scheduled one-on-one meetings. Interested parties should reach out to their Needham sales representatives or contact [email protected] to schedule a one-on-one meeting.

LIBERTY is the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, and it is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain. The Company recently completed the limited market release of the LIBERTY system in the U.S. and commenced its full market release in the U.S. earlier this week at the Society of Interventional Radiology (SIR) Annual Scientific Meeting.

About Microbot Medical

Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot's LIBERTY^® Endovascular Robotic System is the world's first FDA cleared single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.

Learn more at www.microbotmedical.com and connect on LinkedIn and X.